Drug Profile
Research programme: controlled release lipophilic drugs - Nanolymf
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Nanolymf
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Undefined in Israel (PO, Controlled release)
- 21 Dec 2007 Early research in Undefined indication in Israel (PO)